Source: Clinical and Translational Science. Unidades: FMRP, FCFRP
Subjects: HIV, FARMACOCINÉTICA, TUBERCULOSE, ESTUDOS PROSPECTIVOS
ABNT
NARDOTTO, Glauco Henrique Balthazar et al. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, v. 15, p. 514-523, 2022Tradução . . Disponível em: https://doi.org/10.1111/cts.13169. Acesso em: 08 nov. 2024.APA
Nardotto, G. H. B., Bollela, V. R., Rocha, A., Della Pasqua, O., & Lanchote, V. L. (2022). No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, 15, 514-523. doi:10.1111/cts.13169NLM
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1111/cts.13169Vancouver
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1111/cts.13169